|1.||Vanhoutte, F P: 4 articles (05/2007 - 12/2000)|
|2.||Malik, Minnie: 2 articles (07/2014 - 12/2012)|
|3.||Britten, Joy: 2 articles (07/2014 - 12/2012)|
|4.||Catherino, William H: 2 articles (07/2014 - 12/2012)|
|5.||Levy, Gary: 2 articles (07/2014 - 12/2012)|
|6.||Gilden, Melissa: 2 articles (07/2014 - 12/2012)|
|7.||Verfaille, C J: 2 articles (05/2007 - 03/2005)|
|8.||Crump, M: 2 articles (11/2000 - 01/2000)|
|9.||Oza, A: 2 articles (11/2000 - 01/2000)|
|10.||Nabholtz, J M: 2 articles (11/2000 - 01/2000)|
|1.||Prostatic Neoplasms (Prostate Cancer)
05/01/1999 - "We raise the possibility that combination therapy using 1,25-(OH)2D3 and liarozole or other inhibitors of 24-hydroxylase, both in nontoxic doses, might serve as an effective treatment for prostate cancer."
03/01/1998 - "Liarozole appears to be a promising treatment option in prostate cancer."
06/01/1994 - "Phase I liarozole studies in advanced prostate cancer show encouraging results."
05/01/1999 - "Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity."
07/01/1998 - "A total of 321 patients with metastatic prostate cancer in relapse after first-line endocrine therapy entered a Phase III international multicenter study (recruitment from February 1992 to August 1994) comparing liarozole (300 mg two times daily) with CPA (100 mg two times daily). "
|2.||Psoriasis (Pustulosis Palmaris et Plantaris)
03/01/1998 - "Previous studies have shown that liarozole is effective in the treatment of psoriasis. "
12/01/2000 - "The data confirm that liarozole is an effective treatment for psoriasis and indicate that the lowest effective dose is 75 mg twice daily. "
10/01/2001 - "Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study."
12/01/2000 - "A multicentre, double-blind, placebo-controlled, dose-ranging study was therefore undertaken to determine the lowest effective oral dose of liarozole in the treatment of psoriasis vulgaris. "
12/01/2000 - "Treatment of psoriasis with oral liarozole: a dose-ranging study."
|3.||Breast Neoplasms (Breast Cancer)
11/01/2000 - "The clinical responses observed, together with our preclinical results, confirm liarozole's dual mechanism of action and provide a rationale for further evaluation of RAMBAs in the treatment of breast cancer."
01/01/2000 - "Liarozole is an active new treatment for breast cancer in patients heavily pre-treated with hormone therapies. "
01/01/2000 - "Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer."
04/01/1998 - "The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells."
05/15/1992 - "It is concluded that the enhancement by liarozole of the antiproliferative effects of retinoic acid on MCF-7 human breast cancer cells is probably due to inhibition of retinoic acid metabolism. "
05/01/2007 - "The results of this trial warrant further clinical trials to confirm efficacy and safety of liarozole as an orphan drug in ichthyosis."
03/01/2005 - "Topical liarozole in ichthyosis: a double-blind, left-right comparative study followed by a long-term open maintenance study."
01/01/1997 - "This open study showed that oral liarozole treatment was efficacious and well tolerated in the treatment of different types of ichthyosis. "
01/01/1997 - "Twelve male patients with ichthyosis were given oral liarozole, 150 mg twice daily, in an open study for 12 weeks. "
10/01/2001 - "Liarozole has already been found to be effective in the treatment of retinoid-responsive conditions such as chronic plaque psoriasis and ichthyoses. "
11/01/2000 - "Additionally, animal experiments in the MNU-induced rat mammary tumor model and in immature ovariectomized rats were conducted to further elucidate liarozole's mechanisms of action. "
06/01/2000 - "Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole."
09/01/1995 - "In the tumors, a statistically significant accumulation was already noted from 7.5 mg liarozole/kg upwards. "
01/01/1994 - "Liarozole, administered by gavage, twice a day, also significantly reduced median tumor volume in the androgen-independent, AT-6 sq (-90% at 60 mg./kg., twice a day). "
01/01/1994 - "We examined the in vivo antitumoral effects of liarozole against androgen-dependent and independent Dunning rat prostatic tumors. "
|1.||Tretinoin (Retinoic Acid)
|9.||Prostate-Specific Antigen (Semenogelase)
|1.||Drug Therapy (Chemotherapy)